Xue Ruicong, Tan Weiping, Wu Yuzhong, Dong Bin, Xie Zengshuo, Huang Peisen, He Jiangui, Dong Yugang, Liu Chen
Department of Cardiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou, China.
Front Cardiovasc Med. 2020 Dec 17;7:592412. doi: 10.3389/fcvm.2020.592412. eCollection 2020.
Heart failure is the terminal outcome of the majority of cardiovascular diseases, which lacks specific diagnostic biomarkers and therapeutic targets. It contributes to most of cardiovascular hospitalizations and death despite of the current therapy. Therefore, it is important to explore potential molecules improving the diagnosis and treatment of heart failure. MicroRNAs (miRNAs) are small non-coding RNAs that have been reported to be involved in regulating processes of heart failure. After the discovery of miRNAs in exosomes, the subcellular distribution analysis of miRNAs is raising researchers' attention. Growing evidence demonstrates that exosomal miRNAs may be promising diagnostic and therapeutic molecules for heart failure. This review summarizes the role of exosomal miRNAs in heart failure in the prospect of molecular and clinical researches.
心力衰竭是大多数心血管疾病的终末结局，缺乏特异性诊断生物标志物和治疗靶点。尽管有目前的治疗方法，但它仍是大多数心血管住院和死亡的原因。因此，探索改善心力衰竭诊断和治疗的潜在分子很重要。微小RNA（miRNA）是一类小的非编码RNA，据报道其参与心力衰竭的调控过程。在发现外泌体中的miRNA后，miRNA的亚细胞分布分析引起了研究人员的关注。越来越多的证据表明，外泌体miRNA可能是心力衰竭有前景的诊断和治疗分子。本综述从分子和临床研究的角度总结了外泌体miRNA在心力衰竭中的作用。
